Clinical Trials · NCT07571005

AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

Name: AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

RecruitingPhase 3Amycretin

Phase: Phase 3
Recruitment status: Recruiting
Sponsor: Novo Nordisk A/S
Enrollment: 300
Start date: May 2026
Locations: 80 sites, 10 countries
Primary endpoint: Relative change in body weight

View Amycretin compound reference